Hoth Therapeutics ( (HOTH) ) has shared an announcement.
On April 9, 2025, Graig Springer announced his resignation from Hoth Therapeutics‘ Board of Directors and various committees, effective April 15, 2025, with no disagreements cited. Subsequently, Wayne Linsley was appointed as Chair of the nominating and corporate governance committee. On April 15, 2025, Hoth Therapeutics reported positive interim data from its Phase 2a clinical trial of HT-001, showing a 50% reduction in pruritus severity associated with EGFR inhibitors by Day 21, with no serious adverse events, indicating potential relief for cancer patients and enhancing the company’s position in addressing unmet medical needs.
More about Hoth Therapeutics
Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments to improve patient quality of life. The company is involved in early-stage pharmaceutical research and development, advancing drugs from pre-clinical to clinical testing, and collaborates with scientists and clinicians to explore potential therapeutics.
YTD Price Performance: 7.14%
Average Trading Volume: 876,922
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.87M
For a thorough assessment of HOTH stock, go to TipRanks’ Stock Analysis page.